Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Authors:
- Cameron CrowellCCCameron Crowell
- Nikhil P. MankuzhyNMNikhil P. Mankuzhy
- Julie BennettJBJulie Bennett
- Pratiti BandopadhayayPBPratiti Bandopadhayay
- Dominik SturmDSDominik Sturm
- Adam L. GreenAGAdam L. Green
- Tejpal GuptaTejpal Gupta
- Abhishek ChatterjeeACAbhishek Chatterjee
- Sridhar EpariSESridhar Epari
- Girish ChinnaswamyGCGirish Chinnaswamy
- Maya PrasadMPMaya Prasad
- Sohil H. PatelSPSohil H. Patel
Open Access
- 9 March 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (11) , 2243-2254
Abstract
Purpose: Knowledge of prognostic factors and long-term survival in patients with diffuse hemispheric glioma, H3 G34–mutant (DHG, H3 G34), remains limited in this tumor with a poor prognosis. Experimental Design: This retrospective, multi-institutional study investigated prognostic variables for patients with DHG, H3 G34, and their association with progression-free survival (PFS) and overall survival (OS). Uni- and multivariable Cox proportional hazard models were applied with multiple imputed datasets. Results: A total of 153 patients (142 G34R, 9 G34V, 2 via DNA methylation) were included. The median age at diagnosis was 17 years (range, 2–45). Initial gross/near total resection (GTR/NTR) was achieved in 43% of patients. Radiation was given in 91% (85% focal irradiation), and initial chemotherapy was given in 87% [70% temozolomide-based (TMZ), 25% TMZ/lomustine, 5% non-TMZ]. Median OS was 24 months [interquartile range (IQR), 22–28] with a median PFS of 14 months (IQR, 12–19). Twelve patients (8%) were found to be long-term survivors (≥5 years). Exploratory multivariable analysis showed that adjuvant radiotherapy [HR, 0.076; 95% confidence interval (CI), 0.033–0.17] and achieving GTR/NTR compared with < NTR (HR, 0.51; 95% CI, 0.33–0.78) were associated with improved PFS. Multivariable analysis showed improved OS with increasing age at diagnosis (HR, 0.70; 95% CI, 0.57–0.87), initial radiotherapy (HR, 0.38; 95% CI, 0.15–0.96), and initial GTR/NTR compared with < NTR (HR, 0.60; 95% CI, 0.37–0.97). Conclusions: This cohort highlights prognostic factors for patients with DHG, H3 G34, and describes relapse patterns and therapy approaches. Clinical trials and prospective registries are needed to improve outcomes.Keywords
All Related Versions
Funding Information
- IWK Health Centre (1028593)
- IWK Health Centre (1028902)
This publication has 47 references indexed in Scilit:
- Epigenetics to clinicopathological features: a bibliometric analysis of H3 G34-mutant diffuse hemispheric glioma literatureChild's Nervous System, 2024
- A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4Acta Neuropathologica, 2023
- Association of the Extent of Resection With Survival in GlioblastomaJAMA Oncology, 2016
- Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entityActa Neuropathologica, 2015
- Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markersActa Neuropathologica, 2015
- MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPAChild's Nervous System, 2011
- IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology GroupChild's Nervous System, 2010
- MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastomaPediatric Blood & Cancer, 2007
- Cox-Type Regression Analysis for Large Numbers of Small Groups of Correlated Failure Time Observations1992
- Multiple Imputation for Nonresponse in Surveys1987